TL;DR
This study demonstrates the utility of [18F]florbetapir (FBP) PET imaging for early detection and characterization of amyloid deposition in hereditary transthyretin amyloidosis polyneuropathy (hATTR-PN) patients. This non-invasive technique shows promise in identifying organ involvement across various genetic mutations, potentially guiding personalized treatment decisions and monitoring disease progression.
What Problem Does This Paper Address?
Systemic amyloidosis, particularly hereditary transthyretin amyloidosis (hATTR), is a progressive and often fatal disease characterized by the deposition of misfolded proteins in various organs. Hereditary ATTR amyloidosis polyneuropathy (hATTR-PN) presents with a heterogeneous mix of symptoms, including sensory, motor, and autonomic neuropathy, and can also affect the heart. Early diagnosis is crucial for effective treatment, as interventions are most beneficial before severe organ damage occurs. While several imaging modalities exist, including scintigraphy and cardiac MRI, there's a need for non-invasive tools that can accurately detect and characterize amyloid deposition across different organs and genetic subtypes of hATTR-PN. Previous PET tracers have shown promise, but their utility in specific hATTR-PN mutations, especially those less common or not previously studied with PET, remains an area for exploration.
Methods
The study employed whole-body [18F]florbetapir (FBP) PET/CT imaging to assess amyloid deposition in patients with hATTR-PN. FBP is a radiotracer designed to bind to amyloid deposits. The imaging data was analyzed using quantitative metrics such as maximum standardized uptake value (SUVmax) and target-to-background ratio (TBR), with the mediastinal blood pool serving as a reference region. Qualitative visual assessment of amyloid uptake was also performed. The accuracy of FBP PET findings was further validated through histological staining of amyloid deposits in biopsy tissues. The study included a cohort of patients with various hATTR-PN genetic mutations (p.H76R, p.A117S, p.K55N, p.T69A, and the more common p.V50M) and a group of normal controls.
Datasets
The study utilized data from 17 participants: 9 normal controls and 8 patients with hATTR-PN. The hATTR-PN patients carried specific genetic mutations: p.H76R (1 patient), p.A117S (2 patients), p.V50M (2 patients), p.T69A (2 patients), and p.K55N (1 patient). Clinical data, genetic testing results, and biopsy information were collected. No new benchmark datasets were introduced; the study focused on evaluating existing imaging techniques on a specific patient cohort.
Key Insights and Ideas
- Broad Applicability of [18F]FBP PET: The study highlights that [18F]FBP PET can detect amyloid deposition across a range of hATTR-PN genetic mutations, including those not previously studied with this tracer. This suggests a potential for a unified imaging approach for diverse hATTR-PN presentations.
- Early Detection Advantage: [18F]FBP PET identified a greater number and percentage of involved organs compared to clinical evaluation alone, underscoring its role in early and comprehensive disease detection.
- Correlation with Histology: The validation of [18F]FBP PET findings with histological staining of amyloid deposits provides strong evidence for the tracer's accuracy in identifying amyloidosis.
- Differential Uptake Patterns: Different mutations showed distinct patterns of amyloid deposition, which could be valuable for understanding genotype-phenotype correlations and disease progression.
- Absence of CNS Involvement: Notably, the study did not observe central nervous system (CNS) involvement in the hATTR-PN patients studied, contrasting with some reports in other amyloidosis contexts.
Key Results
- [18F]FBP PET imaging revealed amyloid deposition in various organs in hATTR-PN patients, including the heart, kidneys, bone marrow (BM), fat, muscles, stomach, vitreous body, and tongue, depending on the specific genetic mutation.
- Organ involvement by [18F]FBP was most frequently observed in muscle, BM, and kidney (over 85% of patients).
- Quantitative analysis (SUVmax and visual analysis) of [18F]FBP uptake showed a significantly greater number of involved organs in hATTR-PN patients compared to normal controls (p < 0.0001 for both).
- TBR analysis indicated greater [18F]FBP uptake in the liver and BM in hATTR-PN patients compared to normal controls (p < 0.0001 and p = 0.0211, respectively).
- The study found no significant difference between SUVmax and visual analysis in detecting organ involvement.
Limitations and Future Work
- Small Sample Size: The study included a relatively small number of patients (8 hATTR-PN patients), which limits the generalizability of the findings.
- Limited Mutation Coverage: While the study covered several mutations, it did not include all known hATTR-PN mutations.
- Lack of CNS Involvement Observation: The absence of CNS involvement in this cohort warrants further investigation, as other studies have reported it in different contexts.
Future work should focus on larger, multi-center studies to confirm these findings across a broader spectrum of hATTR-PN mutations. Further research into the binding affinity of [18F]FBP for ATTR fibrils with different mutations is needed. The potential of [18F]FBP PET to guide personalized treatment decisions and monitor treatment response, such as with gene silencing therapies or transplantation, should be explored in longitudinal studies.
Summary updated